More data is emerging on the efficacy of several triplet therapies to treat single-class refractory multiple myeloma (MM), potentially giving patients more therapy options than ever before, according to Tel-Aviv Sourasky Medical Center's Yael Cohen, MD, at the European Hematology Association 2023 Congress.
Yael Cohen, MD, vice president of clinical development at VBL Therapeutics and a senior physician in the hematology department at Tel-Aviv Sourasky Medical Center, dived into barriers to access for triplet combinations therapies used to treat multiple myeloma at the European Hematology Association 2023 Congress.
Transcript
What challenges or barriers do patients with single-class refractory multiple myeloma face in achieving a positive treatment response?
So patients in this day and age that have single-class refractory [MM] are typically lenalidomide refractory and this is because most patients today are treated with a [lenalidomide]-based upfront treatment and with long-term lenalidomide so that when they are relapsing, if they are single-drug refractory, it is usually the lenalidomide component—both in the transplant-eligible patients that would typically continue with lenalidomide maintenance after the transplant and also, with the transplant ineligible, the older patients, they will also get some combination at their [treatment] induction and they might be on long-term lenalidomide.
I just want to remark here that going forward, we're probably going to see less patients who were single-class refractory [MM]. We know that for elderly patients, they are getting a DRd [daratumumab and lenalidomide] combination therapy continuing with lenalidomide and daratumumab. So, they will already have 2 drugs [they are refractory to] if they relapse, just as an example.
But if we get back to the lenalidomide-treated refractory patients, in order to have a good response for their next line of treatment when they are a relapsing, of course, we will want to avoid lenalidomide since they are refractory, and we can look at moving to a PI [proteasome inhibitor]-based day regimen including an anti-CD38 drug in the regimen and switching lenalidomide to a more advanced IMiD [immunomodulatory drugs] such as pomalidomide. So, there are many triplets therapies out there that have been investigated in clinical trials.
Probably the most effective regimen and most effective triplets that are less effective from the lenalidomide refractoriness of the patients, as far as the outcomes, are those that combined a CD38 antibody, either daratumumab or isatuximab together with carfilzomib and dexamethasone. They really show a very nice progression-free survival with figures of over 30 months, and again, quite similar, even if you have refractory MM, but of course there are many other triplets out there that can be used in various patients with pomalidomide, bortezomib, and ixazomib with either of the anti-CD38 antibodies.
But certainly, this is a challenge, these lenalidomide-treated refractory patients, because they are certainly an unmet medical need in this day and age. They have worse outcomes than their peers and the data shows that most patients who are exposed to lenalidomide, a vast majority of them are actually refractory to lenalidomide.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More